Coursaget P, Bourdil C, Kastally R, Yvonnet B, Rampanarivo Z, Chiron J P, Bao O, Diop-Mar I, Perrin J, Ntarème F
Institut de Virologie de Tours, Faculté de Pharmacie, France.
Res Virol. 1990 Jul-Aug;141(4):449-54. doi: 10.1016/0923-2516(90)90045-k.
Anti-hepatitis-C-virus (anti-HCV) antibody was tested for in sera from 410 adults living in Tunisia, Senegal, Burundi and Madagascar, and in 209 Tunisian and Senegalese patients suffering from liver diseases. Anti-HCV antibodies were detected in 4.2% of the adult population from Africa, in 51% of patients suffering from liver cirrhosis and in 37% of patients suffering from primary liver cancer. However, higher proportions of anti-HCV antibodies were detected in HBsAg+ patients than in HBsAg- patients. To assess the role of HCV in the development of both cirrhosis and primary liver cancer, a confirmation test is needed.
对居住在突尼斯、塞内加尔、布隆迪和马达加斯加的410名成年人以及209名患有肝脏疾病的突尼斯和塞内加尔患者的血清进行了抗丙型肝炎病毒（抗-HCV）抗体检测。在非洲成年人群中，4.2%检测到抗-HCV抗体；在肝硬化患者中，51%检测到抗-HCV抗体；在原发性肝癌患者中，37%检测到抗-HCV抗体。然而，HBsAg阳性患者中检测到抗-HCV抗体的比例高于HBsAg阴性患者。为了评估HCV在肝硬化和原发性肝癌发展中的作用，需要进行确认试验。
